A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  The Lancet Oncology

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(10)70296-5PMID 21256081PMCID PMC3613042
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The health economics of bladder cancer

  2012cited by this paper
• Neoadjuvant Chemotherapy for Invasive Bladder Cancer

  2012cited by this paper
• The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.

  2010cited by this paper
• Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer

  2010cited by this paper
• Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

  2010cited by this paper
• Statistical consideration for clinical biomarker research in bladder cancer.

  2010cited by this paper
• Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues

  2009cited by this paper
• Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients.

  2009cited by this paper
• Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy.

  2009cited by this paper
• Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial

  2009cited by this paper
• Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.

  2009cited by this paper
• Implementation of a novel microarray‐based diagnostic test for cancer of unknown primary

  2009cited by this paper
• Bladder cancer: narrowing the gap between evidence and practice.

  2009cited by this paper
• Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue.

  2009cited by this paper
• Deep sampling of the Palomero maize transcriptome by a high throughput strategy of pyrosequencing

  2009cited by this paper
• Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.

  2008cited by this paper
• Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer

  2008cited by this paper
• Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer

  2007cited by this paper
• Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

  2007cited by this paper
• A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

  2007cited by this paper
• Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

  2006cited by this paper
• Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

  2006cited by this paper
• Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).

  2005cited by this paper
• Detection of Micrometastases in Pelvic Lymph Nodes in Patients Undergoing Radical Cystectomy for Focally Invasive Bladder Cancer by Real-time Reverse Transcriptase-PCR for Cytokeratin 19 and Uroplakin II

  2005cited by this paper
• Neoadjuvant chemotherapy for invasive bladder cancer.

  2005cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Summaries of Affymetrix GeneChip probe level data.

  2003cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens.

  2000cited by this paper
• Selective bladder preservation by combination treatment of invasive bladder cancer.

  1993cited by this paper

• Unleashing the therapeutic potential of tumor-draining lymph nodes: spotlight on bladder cancer

  2025cites this paper
• Evaluation of gene expression-based predictors of lymph node metastasis in bladder cancer

  2025cites this paper
• Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy

  2025cites this paper
• Artificial intelligence application in the diagnosis and treatment of bladder cancer: advance, challenges, and opportunities

  2024cites this paper
• Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement

  2023cites this paper
• A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study

  2023cites this paper
• MRI radiomics for predicting poor disease-free survival in muscle invasive bladder cancer: the results of the retrospective cohort study

  2023cites this paper
• Predictive nomograms for early death in metastatic bladder cancer

  2023cites this paper
• Identification of potential DNA methylation biomarkers related to diagnosis in patients with bladder cancer through integrated bioinformatic analysis

  2023cites this paper
• Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).

  2023cites this paper
• Biomarkers in muscle invasive bladder cancer.

  2022cites this paper
• Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314.

  2022cites this paper
• Development of a nomogram for predicting lymph node metastasis in patients with urothelial carcinoma of the bladder

  2022cites this paper
• Radiomics Signature Using Manual Versus Automated Segmentation for Lymph Node Staging of Bladder Cancer.

  2022cites this paper
• Pelvic lymph node dissection in prostate and bladder cancers: a narrative review.

  2022cites this paper
• Lymphatic metastasis of bladder cancer: Molecular mechanisms, diagnosis and targeted therapy.

  2021cites this paper
• Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder

  2021cites this paper
• Development and validation of a CT-based nomogram for preoperative prediction of clear cell renal cell carcinoma grades

  2021cites this paper
• An MRI-based radiomics signature and clinical characteristics for survival prediction in early-stage cervical cancer.

  2021cites this paper
• Artificial intelligence in urological oncology: An update and future applications.

  2021cites this paper
• An Exploration of the Tumor Microenvironment Identified a Novel Five-Gene Model for Predicting Outcomes in Bladder Cancer

  2021cites this paper
• Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis

  2021cites this paper
• A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

  2021cites this paper
• A signature of glucose metabolism and DNA methylation improves prognostic prediction for urinary bladder cancer

  2020cites this paper
• The metastatic potential of seminomatous germ cell tumours is associated with a specific microRNA pattern

  2020cites this paper
• Tumor heterogeneity in muscle-invasive bladder cancer

  2020cites this paper
• Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer.

  2020cites this paper
• A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Upstaging.

  2020cites this paper
• An 18-gene signature based on glucose metabolism and DNA methylation improves prognostic prediction for urinary bladder cancer.

  2020cites this paper
• Current applications and challenges of radiomics in urothelial cancer

  2019cites this paper
• A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer

  2019cites this paper
• Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

  2019cites this paper
• Organ preservation in bladder cancer: an opportunity for truly personalized treatment

  2019cites this paper
• Communication Of Cancer Cells And Lymphatic Vessels In Cancer: Focus On Bladder Cancer

  2019cites this paper
• Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer

  2019cites this paper
• OTT_A_219111 8161..8177

  2019cites this paper
• » MTB bieten Patienten die Möglichkeit , unmittelbar von der „ Cutting-edge-Wissenschaft “

  2019cites this paper
• Molekulares Tumorboard – Urothelkarzinom

  2019cites this paper
• A novel gene signature combination improves the prediction of overall survival in urinary bladder cancer

  2019cites this paper
• Development and Validation of an MRI-Based Radiomics Signature for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer

  2018cites this paper
• Chapter 35 – Personalized Medicine

  2018cites this paper
• The New Age of -omics in Urothelial Cancer – Re-wording Its Diagnosis and Treatment

  2018cites this paper
• Personalized Bladder Cancer Management

  2018cites this paper
• The Rho GTPase signalling pathway in urothelial carcinoma

  2018cites this paper
• A Genomic-clinicopathologic Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer

  2018influential citation
• Diagnostic, Prognostic, and Predictive Biomarkers on Bladder Tissue and Blood

  2018cites this paper
• Identification and validation of an 18-gene signature highly-predictive of bladder cancer metastasis

  2018cites this paper
• Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer

  2018cites this paper
• Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors

  2017cites this paper
• Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications

  2017cites this paper
• Minimally Invasive Surgery ( Laparoscopic and Robotic Cystectomy )

  2017cites this paper
• MicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive Phenotype

  2017cites this paper
• Re: Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.

  2017cites this paper
• Extranodal extension of nodal metastasis is the main prognostic moderator in squamous cell carcinoma of the esophagus after neoadjuvant chemoradiotherapy.

  2017cites this paper
• A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable

  2017cites this paper
• A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer

  2017cites this paper
• Predicting the biological behavior of non-muscle-invasive bladder cancer: from histology to molecular taxonomy

  2017cites this paper
• Recent progress with next‐generation biomarkers in muscle‐invasive bladder cancer

  2017cites this paper
• GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis.

  2016cites this paper
• PROGNOSTIC INDICATORS OF LYMPH NODE METASTASIS IN UROTHELIAL BLADDER CANCER

  2016cites this paper
• The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder

  2016cites this paper
• Precision medicine should become more 'sympathetic' in managing hypertension.

  2016cites this paper
• Predicting occult lymph node-positive disease at the time of radical cystectomy: a systematic review.

  2016cites this paper
• Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy

  2016cites this paper
• Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response

  2016cites this paper
• Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?

  2016cites this paper
• A Review of Neoadjuvant and Adjuvant Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer

  2016influential citation
• Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.

  2016cites this paper
• Molecular Pathology of Genitourinary Cancers: Translating the Cancer Genome to the Clinic

  2015cites this paper
• The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer

  2015influential citation
• Individualized management of advanced bladder cancer: Where do we stand?

  2015cites this paper
• External validation of existing nomograms predicting lymph node metastases in cystectomized patients

  2015cites this paper
• Neoadjuvant chemotherapy in the treatment of muscle‐invasive bladder cancer

  2015cites this paper
• Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

  2015cites this paper
• An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer

  2015cites this paper
• Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice.

  2015cites this paper
• Radical cystectomy for muscle-invasive bladder cancer

  2015cites this paper
• Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy

  2015cites this paper
• Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.

  2015influential citation
• Adjuvant chemotherapy for invasive bladder cancer

  2015cites this paper
• Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma

  2015cites this paper
• Treatment of poor risk patients

  2015cites this paper
• De rol van circulerende tumorcellen bij het urotheelcarcinoom van de blaas

  2015cites this paper
• Scoring system for prediction of lymph node metastasis in radical cystectomy cohort

  2014cites this paper
• Expression Signature Defined by FOXM1–CCNB1 Activation Predicts Disease Recurrence in Non–Muscle-Invasive Bladder Cancer

  2014cites this paper
• Molekulare personalisierte Medizin

  2014cites this paper
• Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract

  2014cites this paper
• Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

  2014cites this paper
• Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice.

  2014influential citation
• Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11

  2014cites this paper
• High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer

  2014cites this paper
• Bladder cancer: Bladder preservation—learning what we don't know

  2014cites this paper
• Prognostische und prädiktive molekulare Marker urologischer Tumoren

  2014cites this paper
• Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder

  2014cites this paper
• Multimodal management of muscle-invasive bladder cancer.

  2014cites this paper
• Neoadjuvante chemotherapie voor het spierinvasief urotheelcelcarcinoom van de blaas: een landelijke inventarisatie

  2014cites this paper
• Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

  2014cites this paper
• Microarray gene expression profiling and analysis of bladder cancer supports the sub‐classification of T1 tumours into T1a and T1b stages

  2014cites this paper
• Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives

  2014cites this paper
• A three-gene signature and clinical outcome in esophageal squamous cell carcinoma

  2014cites this paper